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Introduction
Psoriasis is a chronic papulosquamous skin disease that
affects about 2.6% of the United States population [1],
with an equal distribution between men and women. Epi-
dermal hyperplasia in patients with this disease is a
result of T cell-mediated activation of the immune system
in focal areas of the skin [2]. Clinical manifestations of
psoriasis can vary from a silent patch or two of disease
to a generalized plaque or pustular disease or an exfolia-
tive dermatitis. Dermatologists and rheumatologists often
collaborate in the care of patients with psoriatic arthritis
(PsA).
PsA is a seronegative inflammatory arthritis associated
with psoriasis and has been recognized as a specific
disease entity distinct from rheumatoid arthritis (RA) [3]. In
a review of records of patients with psoriasis in Olmsted
County, Minnesota, Shbeeb and colleagues reported that
6.25% of patients with disease confirmed by a dermatolo-
gist also had PsA [4]. Gladman and colleagues investi-
gated the presence of spinal involvement based on clinical
and radiologic evidence in patients with moderate to
severe psoriasis and showed that 35–40% of these
patients have PsA [3,5].
PsA most commonly presents as asymmetric oligoarthritis
or polyarthritis with pain and stiffness that can involve all
peripheral joints. The arthritis manifests as pain and
swelling in the affected joints. There is no direct relation-
ship between the severity of skin lesions and the degree
of joint inflammation in PsA. Other clinical features of PsA
include spondyloarthropathy, tenosynovitis, dactylitis, and
enthesitis [6]. Dactylitis occurs in more than 30% of
patients and is characterized by a diffuse swelling of the
entire digit. Although the exact cause of the cutaneous
and musculoskeletal changes of psoriasis are unknown,
they seem to be the result of a combination of genetic,
immunologic, and environmental factors [7–10].
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Abstract
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset
of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate
to severe cutaneous disease. Analysis of synovial fluid and tissue in patients with PsA demonstrates a
profile of high levels of tumor necrosis factor (TNF) plus other cytokines similar to those seen in
patients with rheumatoid arthritis (RA). In the past, medical management of patients with this disease
consisted of treatment with nonsteroidal anti-inflammatory agents. Patients with more severe disease
have tried a number of different disease-modifying drugs including methotrexate, azathioprine, and gold
salts. However, there is no evidence that these agents can arrest the progress of structural joint
damage. Infliximab and etanercept are TNF antagonists that have demonstrated significant efficacy and
safety in patients with RA. Clinical trials with these two agents in patients with PsA have shown
significant improvement in the rheumatologic and cutaneous manifestations of the disease.
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Activated T cells can be found in both the skin and joints of
patients with PsA [11]. Analysis of synovial tissue and fluid
from patients with psoriatic arthritis reveals greatly increased
levels of tumor necrosis factor (TNF) and other proinflamma-
tory mediators [12,13]. The cytokine pattern in the joint fluid
is similar to that seen in patients with RA, a finding that gen-
erated the hypothesis that TNF antagonists might provide
significant beneficial effects in patients with PsA.
The direct costs of care for patients with psoriasis and its
complications are estimated to exceed $600 million [14].
Shbeeb and colleagues reported that outpatient clinic and
office visits, hospitalizations, and procedures related to
PsA accounted for almost 2% of all psoriasis-related
direct medical costs [4]. Although costs of medications
directly related to treatment could not be precisely deter-
mined from the data, over-the-counter medication costs,
which included both nonsteroidal anti-inflammatory drugs
(NSAIDs) and topical dermatologic preparations, com-
prised more than half of all direct care costs.
This article describes evolving evidence that the TNF antag-
onists can optimize clinical outcomes in patients with PsA.
Medical management of patients with PSA
The treatment of patients with PsA is directed at control-
ling the inflammatory process. Although there is no direct
correlation between joint and skin inflammation in individ-
ual patients, both aspects of the disease need to be
addressed. Treatment usually begins with NSAIDs for joint
disease and topical therapies for the skin [15]. Although
there have been no specific trials of NSAIDs in patients
with PsA, these agents are indicated in mild disease.
However, patients with severe disease should be treated
early and aggressively. Several agents, including
methotrexate, sulfasalazine, cyclosporine A, azathioprine,
and antimalarials, have been used in patients with persis-
tent disease. In patients with severe skin inflammation,
agents such as methotrexate, cyclosporine, oral retinoids,
alefacept, and psoralen plus ultraviolet radiation have
been shown to be effective for skin and joint manifesta-
tions [15–21]. Although these agents can help to control
the symptomatic manifestations of the disease, there is no
evidence that they prevent the progression of clinical and
structural joint damage.
Two-year trials of gold and methotrexate in patients with
PsA have failed to provide evidence that either agent can
arrest the progressive destruction of involved joints
[22,23]. There is therefore an unmet need for better thera-
pies to optimize outcomes and prevent the joint damage
seen in patients with PsA.
Etanercept
Etanercept, a soluble 75 kDa TNF receptor coupled to
part of the Fc fragment of human IgG1 [24], has been
shown to be effective and safe (i.e. FDA approved) in
patients with both PsA and RA and to inhibit the progres-
sion of structural joint disease [25].
Mease and colleagues conducted a 12-week, randomized,
double-blind, placebo-controlled trial to evaluate the efficacy
and safety of etanercept in patients with PsA and psoriasis
[26]. Thirty patients received etanercept 25 mg twice
weekly, administered subcutaneously, and 30 patients
received placebo. Primary study end points for PsA
included the proportions of patients who met the Psoriatic
Arthritis Response Criteria (PsARC) and the American
College of Rheumatology criteria for at least 20% improve-
ment (ACR20). Improvement in the psoriasis area and
severity index (PASI) was one of the end points for psoria-
sis. Study results at 12 weeks showed that 26 (87%) of the
30 etanercept-treated patients met the PsARC, compared
with 7 (23%) of the 30 controls (P < 0.0001). Twenty-two
(73%) of the 30 etanercept-treated patients achieved
ACR20 responses, compared with 4 (13%) of the 30 con-
trols (P < 0.0001). The median improvement in the PASI
was 46% in the etanercept-treated patients and 9% in the
controls. No serious adverse events were reported in the
patients receiving etanercept.
On the basis of these study results, Mease and colleagues
conducted a randomized, 24-week, double-blind, placebo-
controlled trial in 205 patients who had an inadequate
response to their current therapy [27]. Inclusion criteria
included stable plaque psoriasis with a qualifying target
lesion, plus active PsA with at least three swollen and
three tender joints. PsA was characterized by at least one
manifestation of distal interphalangeal involvement, poly-
articular disease, arthritis mutilans, asymmetric disease, or
ankylosing spondylitis-like symptoms. Patients could con-
tinue on stable doses of NSAIDs, corticosteroids, and
methotrexate at a dosage of less than 25 mg per week,
but other therapeutic interventions, including disease-
modifying antirheumatic drugs (DMARDs), psoralen, ultra-
violet A and B radiation, topical steroids, vitamins A and D,
anthralin, and oral retinoids were to be discontinued
2–4 weeks before the study. Patients who met the entry
criteria were randomized to receive subcutaneous injec-
tions of etanercept 25 mg or placebo twice weekly.
Study results at 12 weeks showed statistically significant
improvement with etanercept, as demonstrated by the
numbers of patients who achieved the ACR20
(P < 0.0001), the ACR50, indicating at least 50%
improvement in ACR criteria (P < 0.0001), and the
ACR70, indicating at least 70% improvement in ACR cri-
teria (P = 0.009) compared with controls (Fig. 1) [27].
These differences were still significantly greater than
those observed in the controls at 24 weeks, but the
response rates with etanercept did not improve from
12 weeks.S33
At 24 weeks, the authors evaluated improvements in PASI
in a subpopulation of patients with psoriasis over 3% or
more of their body surface area. A 50% improvement in
PSAI was recorded in 47% of etanercept-treated patients
compared with 23% of controls, and a 75% improvement
in PSAI was recorded in 18% of etanercept-treated
patients compared with 3% of controls. Injection site reac-
tions were the most frequently reported adverse event
with etanercept, and occurred significantly more fre-
quently than with placebo (P < 0.001). Otherwise, etaner-
cept was well tolerated.
Infliximab
Infliximab, a chimeric protein formed by a murine anti-TNF
Fab fragment plus the constant region of human IgG1κ
[24], has been shown to be effective and safe in patients
with RA, to improve physical functioning, and to prevent
the progression of structural joint disease [28].
Several small studies have been conducted to evaluate the
efficacy and safety of infliximab in patients with PsA. Van
den Bosch and colleagues conducted a 12-week, double-
blind, placebo-controlled trial in 40 patients with active
spondyloarthropathy, 18 of whom had PsA [29]. The
primary study end point was improvement in patient and
physician global assessments on a 100 mm visual analog
scale. Patients were randomized to receive infliximab
5 mg/kg intravenously at 0, 2, and 6 weeks, or placebo.
Although there were too few PsA patients on whom to
conduct a separate analysis, the infliximab-treated patients
demonstrated statistically significant improvement
(P < 0.001) from baseline in patient global assessment,
physician global assessment, erythrocyte sedimentation
rate, and C-reactive protein level, compared with controls.
Infliximab was generally well tolerated, although one patient
developed disseminated tuberculosis.
Cauza and colleagues evaluated the efficacy and safety of
infliximab in nine patients with active psoriasis and PsA.
Patients received five infusions of infliximab 3 mg/kg over
22 weeks [30]. Infliximab produced ACR20, ACR50, and
ACR70 responses in 89%, 56%, and 22% of the patients,
respectively; these responses were sustained through
22 weeks of treatment. In addition, there was significant
improvement (P = 0.002) in PASI scores. Infliximab was
well tolerated.
Antoni and colleagues evaluated the efficacy and safety of
infliximab in a 54-week open-label study. Ten patients with
PsA refractory to other medical interventions were adminis-
tered infliximab 5 mg/kg intravenously at 0, 2, and 6 weeks,
with individualized dosing after 10 weeks [31]. Patients
were assessed at 2, 6, 10, and 54 weeks, and magnetic
resonance imaging (MRI) was performed at 0 and 10 weeks
to measure joint inflammation. All patients demonstrated an
ACR20 response by 2 weeks, and eight patients improved
to demonstrate an ACR70 response at 10 weeks, which
was maintained to 54 weeks in six patients. At 10 weeks the
PSAI scores were significantly improved with infliximab
(P = 0.003) in this last subset of six patients, with a mean
71.3% reduction from baseline. The MRI at 10 weeks
showed an 82.5% mean reduction in inflammation from
baseline. There were no significant adverse events, severe
infections, or infusion-related reactions.
The positive results in these small studies led to the
design of the Infliximab Multinational Psoriatic Arthritis
Controlled Trial (IMPACT), a 16-week, multicenter, multi-
national, double-blind, placebo-controlled study in 100
patients with active PsA who failed therapy with one or
more DMARDs [32]. Patients were randomized to receive
infliximab 5 mg/kg intravenously at 0, 2, 6, and 14 weeks,
or placebo. After completion of the randomized, controlled
phase of the trial, patients were eligible to enter an open-
label follow-up phase during which infliximab was adminis-
tered at 8-week intervals for up to 2 years. Sixty-nine
patients were taking concomitant DMARDs, and 56
patients were taking methotrexate. At 16 weeks, an
ACR20 response was reported in 69% of infliximab-
treated patients compared with 8% of controls
(P < 0.001), an ACR50 response was reported in 49% of
infliximab-treated patients compared with 0% of controls
(P < 0.0001), and an ACR70 response was reported in
29% of infliximab-treated patients compared with 0% of
controls (P < 0.0001) (Fig. 2) [32]. Analysis showed no
differences in ACR results in infliximab-treated patients
who were or were not taking concomitant methotrexate.
Evaluation of a subpopulation of patients with psoriasis
over 3% or more of their body surface area showed that
infliximab-treated patients demonstrated an 81% improve-
ment in PSAI compared with a 35% worsening in controls
(P < 0.001). Infliximab was well tolerated, with no differ-
ence in the incidence of adverse events from placebo.
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Figure 1
Percentage of etanercept- and placebo-treated patients demonstrating
ACR20, ACR50, and ACR70 responses at 24 weeks. ACR, American
College of Rheumatology. *P < 0.0001. †P = 0.009. Reproduced with
permission from John Wiley & Sons, Inc. [27]. © 2001 American
College of Rheumatology
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There were no serious infections or cases of tuberculosis,
and there was one discontinuation of the drug owing to an
infusion-related reaction.
Conclusion
PsA is a chronic, progressive disease that tends to
respond poorly to several currently used agents. Biologic
response modifier therapy with TNF antagonists repre-
sents a major step in improving functional outcomes in
these patients. So far, etanercept has been approved for
the treatment of active PsA. However, both infliximab and
etanercept significantly improve the clinical, laboratory,
and statistical markers of cutaneous and articular disease.
Both agents are safe and well tolerated. Issues currently
under study with the TNF antagonists include the optimum
dose and schedule, patient selection criteria, the effects of
concomitant therapy, and the role of these agents in pre-
venting structural damage.
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Figure 2
Percentage of infliximab- and placebo-treated patients demonstrating
ACR20, ACR50, and ACR70 responses at 16 weeks. ACR, American
College of Rheumatology. P < 0.0001. Reproduced with permission
from [32].
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